On October 1, 2026, BioCardia, Inc. (Nasdaq: BCDA) filed a Current Report on Form 8-K announcing the completion of a revised Pre-Submission to the FDA Center for Devices and Radiological Health (CDRH) under the Q-Submission program. The submission concerns the company's Helix Catheter, a device designed for the delivery of therapeutic and diagnostic agents to the heart.
The filing references a press release dated October 1, 2026, which details the regulatory history of the device. In May 2026, BioCardia and the FDA met to review an initial De Novo pre-submission. The FDA reportedly agreed that there are two potential pathways for marketing clearance of the Helix Catheter and raised no concerns regarding the device's safety data, performance, or compatibility with general classes of agents.
In August 2026, the FDA confirmed and accepted meeting minutes summarizing the discussions. The revised submission incorporates advice provided by the FDA CDRH during these meetings. The company notes that if the FDA approves the Helix Catheter as the first device of its kind, it could establish a precedent for future devices to demonstrate non-inferiority to the Helix safety profile prior to their own clearance.
The company provided specific timelines for the FDA's review process. The FDA targets providing an initial acceptance or refusal review within 15 calendar days and aims to issue written feedback or schedule a meeting within 70 calendar days.
BioCardia states that an independent clearance of the Helix Catheter has the potential to expand opportunities for the company to partner with developers of investigational cell, gene, and protein therapeutics that require targeted delivery to the heart.
